On Tuesday, PTC Therapeutics Inc (NASDAQ: PTCT) opened lower -0.48% from the last session, before settling in for the closing price of $49.76. Price fluctuations for PTCT have ranged from $28.72 to $58.38 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 23.09%. Company’s average yearly earnings per share was noted 19.58% at the time writing. With a float of $76.82 million, this company’s outstanding shares have now reached $77.70 million.
Let’s determine the extent of company efficiency that accounts for 939 employees. In terms of profitability, gross margin is 86.14%, operating margin of -36.67%, and the pretax margin is -45.01%.
PTC Therapeutics Inc (PTCT) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of PTC Therapeutics Inc is 2.60%, while institutional ownership is 97.51%. The most recent insider transaction that took place on Apr 22 ’25, was worth 136,656. In this transaction CHIEF EXECUTIVE OFFICER of this company sold 2,804 shares at a rate of $48.74, taking the stock ownership to the 273,234 shares. Before that another transaction happened on Apr 22 ’25, when Company’s Officer proposed sale 2,804 for $48.74, making the entire transaction worth $136,656.
PTC Therapeutics Inc (PTCT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.18 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 19.58% per share during the next fiscal year.
PTC Therapeutics Inc (NASDAQ: PTCT) Trading Performance Indicators
Check out the current performance indicators for PTC Therapeutics Inc (PTCT). In the past quarter, the stock posted a quick ratio of 2.31. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.73, a number that is poised to hit -1.01 in the next quarter and is forecasted to reach -2.20 in one year’s time.
Technical Analysis of PTC Therapeutics Inc (PTCT)
Looking closely at PTC Therapeutics Inc (NASDAQ: PTCT), its last 5-days average volume was 0.73 million, which is a drop from its year-to-date volume of 0.88 million. As of the previous 9 days, the stock’s Stochastic %D was 85.05%. Additionally, its Average True Range was 2.77.
During the past 100 days, PTC Therapeutics Inc’s (PTCT) raw stochastic average was set at 57.93%, which indicates a significant decrease from 91.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.10% in the past 14 days, which was higher than the 49.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $50.45, while its 200-day Moving Average is $42.74. However, in the short run, PTC Therapeutics Inc’s stock first resistance to watch stands at $50.13. Second resistance stands at $50.73. The third major resistance level sits at $51.38. If the price goes on to break the first support level at $48.88, it is likely to go to the next support level at $48.23. Should the price break the second support level, the third support level stands at $47.63.
PTC Therapeutics Inc (NASDAQ: PTCT) Key Stats
There are currently 78,869K shares outstanding in the company with a market cap of 3.91 billion. Presently, the company’s annual sales total 806,780 K according to its annual income of -363,300 K. Last quarter, the company’s sales amounted to 213,170 K and its income totaled -65,890 K.
